Characterization of triple negative breast cancer gene expression profiles in Mexican patients

• DOI: 10.3892/mco.2022.2601
• Publication Date: 2022-12-15T08:12:48Z
• Authors: Eric Ortiz Valdez; Claudia Rangel‑Es...; Juan Antonio Matu...; Rafael Vázquez Romo; Alberto Guijosa; Cynthia Villarrea...; Oscar Arrieta; Rubén Rodríguez‑B...; Claudia Caro‑Sánchez; Alette Ortega Gómez
• Keywords: Triple-negative breast cancer

Triple negative breast cancer (TNBC) is an aggressive type of that accounts for ~23% tumors in Mexico. In attempt to understand improved way the behavior TNBC, throughout years, gene expression these has been studied. Lehman et al identified 6 subtypes TNBC with distinct characteristics. present study, it was aimed assess clinical, pathological and prognostic characteristics a Mexican-based cohort. A total 55 patients diagnosed at Mexico's National Institute Cancer (INCan) were included. Tumor needle biopsy samples obtained subjected microarray analysis. Patients thus classified into one molecular subtypes. The prognostic, clinical information obtained, differences across sought. Out included patients, following identified: 9 basal-like-1, 11 basal-like-2 (BSL2), 16 immunomodulatory (IM), 12 mesenchymal, androgen receptor-like 1 mesenchymal stem-like. Mean follow-up time 47.1 months. IM subtype had best overall survival (OS) (median OS not reached). BSL2 worst (15 months). complete pathologic response neoadjuvant chemotherapy more often (P=0.032). No significant associations found between any or results from study should be considered when seeking implement clinical-molecular model patient care, particularly Hispanic-based populations, as they have frequently underrepresented studies assessing